T1	Participants 72 103	patients with prostatic cancer.
T2	Participants 294 334	patients (N = 100) with prostatic cancer
T3	Participants 1530 1561	patients with prostatic cancer.
T4	Participants 1739 1759	prostatic carcinoma.
